English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 854896      Online Users : 871
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/5015


    Title: Antiangiogenic Activities and Cisplatin-combined Antitumor Activities of BPR0L075
    Authors: Chen, CP;Hu, CB;Yeh, KC;Song, JS;Yeh, TK;Tung, FF;Hwang, LL;Tseng, HY;Huang, YC;Shy, HS;Hsieh, SH;Shen, CC;Wang, HS;Hsieh, HP;Liou, JP;Chao, YS;Chen, CT
    Contributors: Division of Biotechnology and Pharmaceutical Research
    Abstract: Background: Antimitotic tubulin-binding BPR0L075 is structurally analogous to the vascular-disrupting combretastatin A-4. Materials and Methods: In vitro/in vivo models of endothelial cells cultures, Matrigel (TM) plug assay, tumor-bearing nude mice, and murine leukemia cells-inoculated mice were utilized to evaluate BPR0L075 for antiangiogenic and antitumoral activity spectra. Results: BPR0L075 concentration-dependently inhibited proliferation and migration of human umbilical vein endothelial cells (HUVECs), disrupted capillary tube formations of HUVECs and rat aorta endothelial cells, and suppressed in vivo VEGF-mediated angiogenesis in Matrigel (TM) plugs in mice. Besides inhibiting the colony growth of cancer cells, BPR0L075 suppressed growth of subcutaneously-xenografted human lung, colorectal, and cervical solid tumors in nude mice. Combination treatments of BPR0L075 plus cisplatin, compared to either agent alone, demonstrated a stronger growth inhibition against the tumor xenografts in nude mice and longer lifespan in the leukemia mice. Conclusion: BPR0L075 is an antitumoral and antiangiogenic agent and potentiates the anticancer activity of cisplatin.
    Date: 2010-07
    Relation: Anticancer Research. 2010 Jul;30(7):2813-2822.
    Link to: http://ar.iiarjournals.org/content/30/7/2813.abstract
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0250-7005&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000280796400046
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955799467
    Appears in Collections:[趙宇生(2002-2013)] 期刊論文
    [葉燈光] 期刊論文
    [陳炯東] 期刊論文
    [謝興邦] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISI000280796400046.pdf355KbAdobe PDF546View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback